Image credit: Canva
Multiple myeloma is an incurable cancer of certain blood cells that often returns after treatment. To improve survival, researchers want to find ways to identify the disease earlier when it returns. A clinical trial led by Elizabeth M. Hill, M.D., Assistant Research Physician in the Lymphoid Malignancies Branch, is studying a radiotracer that may be a useful detection method for multiple myeloma.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact the NCI Medical Oncology Referral Office at (888) 624-1937 or ncimo_referrals@nih.gov.
Clinicaltrials.gov identifier: NCT06103838
NCI Protocol ID: IRB001525
Official Title: A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow, treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
